VIRAL HEPATITIS B AND C AS COMORBIDITY IN RHEUMATIC DISEASES: ANALYSIS OF THE DATA OF THE V.A. NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY CLINIC OVER 4 YEARS
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is a serious problem that substantially hinders the treatment of patients with rheumatic diseases (RD) particular when there is a need for using cytotoxic and biological agents (BAs).Objective: to estimate the rate of HBV and HCV infectio...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2016-07-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2227 |
id |
doaj-0e7232ca58bf4ab6a192fff5e8c1b3d9 |
---|---|
record_format |
Article |
spelling |
doaj-0e7232ca58bf4ab6a192fff5e8c1b3d92021-08-02T09:05:48ZrusIMA-PRESS LLCНаучно-практическая ревматология1995-44841995-44922016-07-0154331832310.14412/1995-4484-2016-318-3232102VIRAL HEPATITIS B AND C AS COMORBIDITY IN RHEUMATIC DISEASES: ANALYSIS OF THE DATA OF THE V.A. NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY CLINIC OVER 4 YEARSA. E. Karateev0N. V. Gontarenko1A. V. Tsurgan2A. A. Abramkin3L. D. Vorobyeva4D. V. Bukhanova5V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyHepatitis B virus (HBV) and hepatitis C virus (HCV) infection is a serious problem that substantially hinders the treatment of patients with rheumatic diseases (RD) particular when there is a need for using cytotoxic and biological agents (BAs).Objective: to estimate the rate of HBV and HCV infection in RD patients followed up at the V.A. Nasonova Research Institute of Rheumatology Clinic in 2011 to 2014.Subjects and methods. All case histories of the RD patients hospitalized in the given period were analyzed. Infection with HBV and HCV was assessed from the presence of HBsAg and anti-HCV, respectively.Results and discussion. There were a total of 16,553 admissions to the V.A. Nasonova Research Institute of Rheumatology Clinic over 4 years. HBV and HCV were detected in 0.33 and 0.74%, respectively; their combination was found in 0.03% (a total of 1.1%) of the patients. About half of the patients took cytotoxic agents and glucocorticoids; 29.8% received BAs, mainly rituximab. Moderate and high chronic hepatitis activity was noted in 4.9% of the patients; liver cirrhosis was observed in 2.7%. Over the follow-up period, alanine aminotransferase and aspartate aminotransferase levels were not elevated in the vast majority of patients.Conclusion. HBV and HCV infection is often detected in patients with RD. The infected patients and persons with chronic viral hepatitis require careful follow-up and the decision whether to perform prophylactic antiviral therapy when using cytotoxic agents and BAs.https://rsp.mediar-press.net/rsp/article/view/2227rheumatic diseaseshepatitis b virushepatitis c viruschronic viral hepatitiscytotoxic agentsbiological agents |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
A. E. Karateev N. V. Gontarenko A. V. Tsurgan A. A. Abramkin L. D. Vorobyeva D. V. Bukhanova |
spellingShingle |
A. E. Karateev N. V. Gontarenko A. V. Tsurgan A. A. Abramkin L. D. Vorobyeva D. V. Bukhanova VIRAL HEPATITIS B AND C AS COMORBIDITY IN RHEUMATIC DISEASES: ANALYSIS OF THE DATA OF THE V.A. NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY CLINIC OVER 4 YEARS Научно-практическая ревматология rheumatic diseases hepatitis b virus hepatitis c virus chronic viral hepatitis cytotoxic agents biological agents |
author_facet |
A. E. Karateev N. V. Gontarenko A. V. Tsurgan A. A. Abramkin L. D. Vorobyeva D. V. Bukhanova |
author_sort |
A. E. Karateev |
title |
VIRAL HEPATITIS B AND C AS COMORBIDITY IN RHEUMATIC DISEASES: ANALYSIS OF THE DATA OF THE V.A. NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY CLINIC OVER 4 YEARS |
title_short |
VIRAL HEPATITIS B AND C AS COMORBIDITY IN RHEUMATIC DISEASES: ANALYSIS OF THE DATA OF THE V.A. NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY CLINIC OVER 4 YEARS |
title_full |
VIRAL HEPATITIS B AND C AS COMORBIDITY IN RHEUMATIC DISEASES: ANALYSIS OF THE DATA OF THE V.A. NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY CLINIC OVER 4 YEARS |
title_fullStr |
VIRAL HEPATITIS B AND C AS COMORBIDITY IN RHEUMATIC DISEASES: ANALYSIS OF THE DATA OF THE V.A. NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY CLINIC OVER 4 YEARS |
title_full_unstemmed |
VIRAL HEPATITIS B AND C AS COMORBIDITY IN RHEUMATIC DISEASES: ANALYSIS OF THE DATA OF THE V.A. NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY CLINIC OVER 4 YEARS |
title_sort |
viral hepatitis b and c as comorbidity in rheumatic diseases: analysis of the data of the v.a. nasonova research institute of rheumatology clinic over 4 years |
publisher |
IMA-PRESS LLC |
series |
Научно-практическая ревматология |
issn |
1995-4484 1995-4492 |
publishDate |
2016-07-01 |
description |
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is a serious problem that substantially hinders the treatment of patients with rheumatic diseases (RD) particular when there is a need for using cytotoxic and biological agents (BAs).Objective: to estimate the rate of HBV and HCV infection in RD patients followed up at the V.A. Nasonova Research Institute of Rheumatology Clinic in 2011 to 2014.Subjects and methods. All case histories of the RD patients hospitalized in the given period were analyzed. Infection with HBV and HCV was assessed from the presence of HBsAg and anti-HCV, respectively.Results and discussion. There were a total of 16,553 admissions to the V.A. Nasonova Research Institute of Rheumatology Clinic over 4 years. HBV and HCV were detected in 0.33 and 0.74%, respectively; their combination was found in 0.03% (a total of 1.1%) of the patients. About half of the patients took cytotoxic agents and glucocorticoids; 29.8% received BAs, mainly rituximab. Moderate and high chronic hepatitis activity was noted in 4.9% of the patients; liver cirrhosis was observed in 2.7%. Over the follow-up period, alanine aminotransferase and aspartate aminotransferase levels were not elevated in the vast majority of patients.Conclusion. HBV and HCV infection is often detected in patients with RD. The infected patients and persons with chronic viral hepatitis require careful follow-up and the decision whether to perform prophylactic antiviral therapy when using cytotoxic agents and BAs. |
topic |
rheumatic diseases hepatitis b virus hepatitis c virus chronic viral hepatitis cytotoxic agents biological agents |
url |
https://rsp.mediar-press.net/rsp/article/view/2227 |
work_keys_str_mv |
AT aekarateev viralhepatitisbandcascomorbidityinrheumaticdiseasesanalysisofthedataofthevanasonovaresearchinstituteofrheumatologyclinicover4years AT nvgontarenko viralhepatitisbandcascomorbidityinrheumaticdiseasesanalysisofthedataofthevanasonovaresearchinstituteofrheumatologyclinicover4years AT avtsurgan viralhepatitisbandcascomorbidityinrheumaticdiseasesanalysisofthedataofthevanasonovaresearchinstituteofrheumatologyclinicover4years AT aaabramkin viralhepatitisbandcascomorbidityinrheumaticdiseasesanalysisofthedataofthevanasonovaresearchinstituteofrheumatologyclinicover4years AT ldvorobyeva viralhepatitisbandcascomorbidityinrheumaticdiseasesanalysisofthedataofthevanasonovaresearchinstituteofrheumatologyclinicover4years AT dvbukhanova viralhepatitisbandcascomorbidityinrheumaticdiseasesanalysisofthedataofthevanasonovaresearchinstituteofrheumatologyclinicover4years |
_version_ |
1721235717803212800 |